Proteomic technologies for biomarker studies in psychiatry: advances and needs.

In the postgenome era, proteomics has arisen as a promising tool for more complete comprehension of diseases and for biomarker discovery. Some of these objectives have already been partly achieved for illnesses such as cancer. In the case of psychiatric conditions, however, proteomic advances have had a less profound impact. Here, we outline the necessity of improving and applying proteomic methods for biomarker discovery and validation in the field of psychiatric disorders. While proteomic-based applications in neurosciences have increased in accuracy and sensitivity over the past 10 years, the development of orthogonal validation technologies has fallen behind. These issues are discussed along with the importance of integrating systems biology approaches and combining proteomics with other research approaches. The future development of such technologies may put proteomics closer to clinical applications in psychiatry. Copyright © 2011 Elsevier Inc. All rights reserved.

Citation

Daniel Martins-de-Souza, Paul C Guest, Natacha Vanattou-Saifoudine, Laura W Harris, Sabine Bahn. Proteomic technologies for biomarker studies in psychiatry: advances and needs. International review of neurobiology. 2011;101:65-94

Mesh Tags

Substances

PMID: 22050849

search → result